Fig. 8
Antitumor activity of G8 TCR-T cells against cervical cancer in a mouse model. a–c NCG mice with 21-day subcutaneous CaSki-luc tumors were treated with a single intravenous injection of 4 × 106 G8 TCR+ T cells. 50,000 IU IL-2 was given daily by intraperitoneal injection for 3 days. Ctrl-T: NCG mice were treated with untransduced T cells and IL-2. PBS: NCG mice were treated with PBS and IL-2. a Tumor growth was monitored by bioluminescence imaging at indicated time points. b Quantitative imaging data of figure A (n = 5). c Tumors excised from mice in each group on day 27 after TCR-T cell treatment. *p < 0.05. An unpaired two-tailed t test was performed